# Session handoff — resume 3

Initiative: `biostack-go-live`
Date: 2026-10-14
Agent: coordinator resume session
Decision: **NO-GO / HOLD**
Resume 4 (`SESSION-2026-10-14-resume-4.md`) is now the operational record. The production probe below still stands. Nothing recorded in resume 4 was deployed. This file does not authorize production release and does not change `docs/INITIATIVES/biostack-production-readiness/`.

Publish facts in `HANDOFF-2026-10-14.md` still stand. Where `STATUS.md` still describes the security and checkout work as uncommitted, this file wins.

## Starting state

- Local branch: `docs/go-live-library-record`
- Local `HEAD`: `5b686e69536f2eedf0195ee77466f20b08a490d8`
- `origin/main`: `9550964256d507d03b789df8f0eb4c448a6f7ac8` (merge of PR #545, parent is this `HEAD`)
- `origin/dev`: `6c9d8eccfd69f848d69c223e547c4d40dbf6ccee` (does not contain PR #544 or PR #545)
- Worktree `D:/Repos/BioStack/.worktrees/bio-golive-security-checkout` is clean at `b3cdde20323f554f0519dc57bfc1c1395241fbc8` on `fix/go-live-security-and-checkout`

Untracked and left untouched: `.memory/`, and a stray untracked path named `--nologo`.

## What is true now

PR #544 merged the security and checkout source fix to `main` at `2026-10-14T16:59:20Z`. Commit `b3cdde20` guards OpenAPI and Scalar with `!IsProduction()`, partitions auth and lead-capture limits through `ClientIpResolver`, adds an auth-start account budget, validates lead email and source, redacts logged emails and magic links, claims the Stripe webhook receipt before side effects, and passes the chosen plan into `createCheckoutSession`. PR #545 then merged the library record, the three review-candidate specs, and the seed onto `main`.

No Gate 2 record exists for BIO-GOLIVE-001, BIO-GOLIVE-002, or BIO-GOLIVE-003. All three remain `review-candidate` in `docs/specs/INDEX.md`. The merged source is not an approved parcel and is not production evidence.

Deploy of that source did not reach Azure. The last successful `Deploy to Azure Container Apps` run is [38136962345](https://github.com/m0r6aN/biostack/actions/runs/38136962345) for `6c9d8ecc` on 2026-10-11. Runs [38602773660](https://github.com/m0r6aN/biostack/actions/runs/38602773660) (PR #544) and [38603798795](https://github.com/m0r6aN/biostack/actions/runs/38603798795) (PR #545) failed in `Reject high-severity backend dependency advisories` before backend tests and before Azure login. The failing advisories are NU1903:

- `System.Security.Cryptography.Pkcs` 10.0.10 and, on the API project, 9.0.0 — [GHSA-846f-f764-76mx](https://github.com/advisories/GHSA-846f-f764-76mx)
- `System.Security.Cryptography.Xml` 10.0.10 — [GHSA-7hqp-7c5m-4vq6](https://github.com/advisories/GHSA-7hqp-7c5m-4vq6), [GHSA-c399-9853-6jmj](https://github.com/advisories/GHSA-c399-9853-6jmj), [GHSA-r955-8q5j-3h83](https://github.com/advisories/GHSA-r955-8q5j-3h83)

Read-only production GETs on 2026-10-14, after a first OpenAPI request canceled at 25 seconds:

| Probe | Result |
|---|---|
| `GET https://api.biostack.cc/openapi/v1.json` | **200** in 378 ms. 92,651 bytes. F-001 still open in production. |
| `GET https://api.biostack.cc/scalar/v1` | **200** in 218 ms. HTML title `BioStack Mission Control API`. F-001 still open. |
| `GET https://api.biostack.cc/health` | 200. Body `Healthy`. |
| `GET https://api.biostack.cc/api/v1/knowledge/compounds/Glycine` | 200. `classification` **Unknown**. |
| `GET https://api.biostack.cc/api/v1/knowledge/compounds/Retatrutide` | 200. `classification` **Unknown**. |

`SubstanceCanonicalizer.MapClassification` still stores `Amino Acid` and `Research Compound` as `Unknown`. BIO-GOLIVE-001 is not implemented.

The committed seed at `HEAD` classifies Retatrutide as `Peptide` and includes the alias `triple agonist`. The promotion batch `go-live-library-2026-10-14-retatrutide` still names no class. BIO-GOLIVE-001 acceptance remains `ResearchCompound`. The committed Peptide value is seed drift. It is not the acceptance class, and this session did not edit the seed or run Refresh.

## Files changed

- `docs/INITIATIVES/biostack-go-live/STATUS.md`
- `docs/INITIATIVES/biostack-go-live/SESSION-2026-10-14-resume-3.md`
- `docs/specs/active/BIO-GOLIVE-001-public-classification-and-list-read.md`
- `docs/INITIATIVES/biostack-go-live/reviews/BIO-GOLIVE-001-spec-review-1.md`
- `docs/INITIATIVES/biostack-go-live/reviews/BIO-GOLIVE-001-spec-review-2.md`
- `docs/INITIATIVES/biostack-go-live/reviews/SECURITY-RECHECK-PR544-2026-10-14.md`

## Verification result

Production class labels and F-001 remain failed. No product test was run. No product code was edited.

## Decisions needed

None that block the next safe action. The committed Retatrutide class `Peptide` stays unreviewed. A later promotion parcel must name the class before a repair writes one. This session does not choose it.

## Blockers

- BIO-GOLIVE-001 is a review candidate. Public Glycine and Retatrutide `classification` are `Unknown`.
- PR #544 source is on `main` without Gate 2 and without an independent re-check.
- `main` cannot pass the deploy workflow while the NU1903 high advisories fail the restore.
- F-004 through F-007 stay open and blocking. F-005 remains counsel-owned.
- Counsel approval, spend, drills, and billing lifecycle remain human-owned.

## Review triage

Both BIO-GOLIVE-001 spec reviews returned **FAIL**. The coordinator reproduced the blockers and amended the spec. It stays `review-candidate`. The linter returned `valid`. Gate 2 is not open.

| Review | Verdict | Disposition |
|---|---|---|
| `reviews/BIO-GOLIVE-001-spec-review-1.md` | FAIL | Accepted. Fact 5 was false on this tree. `GetAllCompoundsAsync` is shared. The cold 3-second line was not measurable. |
| `reviews/BIO-GOLIVE-001-spec-review-2.md` | FAIL | Accepted. Criterion 7 required live labels that the same spec forbade the parcel from writing. Retatrutide's committed class is Peptide and its promotion record names no class. |
| `reviews/SECURITY-RECHECK-PR544-2026-10-14.md` | Not a clearance | Accepted. F-001 source-addresses-finding, production-open. F-002, F-003, F-004, F-006, and F-007 are source-partial. F-005 stays open. Frontend tests for the checkout plan path passed: 3 files, 9 tests. Signed-in Commander success is not asserted. |

The amendment keeps Retatrutide's Peptide seed value unreviewed. This parcel no longer treats live `AminoAcid` or `ResearchCompound` as its own acceptance. `ListPublicCompoundsAsync` is a new method. `GetAllCompoundsAsync` stays a full-entity read. Cold-start time is not a pass or fail.

`ClientIpResolver` trusts every private and CGNAT peer and then the leftmost `X-Forwarded-For` hop. `BillingService.ProcessStripeEventAsync` deletes the claimed receipt on a later exception. Those source-partial findings stand.

## Next safe action

1. Send the amended BIO-GOLIVE-001 spec to two new independent reviewers. Do not create its worktree until those reviews pass and Gate 2 names the spec hash.
2. Shape a review-candidate remediation spec for the source-partial findings F-002, F-003, F-004, F-006, and F-007. Do not treat PR #544 as closed.
3. Shape a review-candidate parcel for the NU1903 deploy block. Do not bump packages in this session.

## Do not touch

- Production Refresh, unless the seed file changes under an approved parcel and a new dry run is read first.
- `ConnectionStrings__DefaultConnection` and Container App secrets.
- Live Stripe charges, refunds, and cancellations.
- Terms, privacy, disclaimer, and subscription-policy approval.
- The production-readiness initiative's NO-GO.
- Dose, schedule, and pairing `JsonIgnore` attributes on the public compound response.
- The Retatrutide seed class.
- Another 150-entry generation.
